Model-Based Meta-Analysis

What can we quantify with model-based meta-analysis (MBMA)?

Comparative safety and efficacy profile
There are very few active comparator trials in drug development, however it is often important to assess a compound’s safety and efficacy profile in comparison to SOC and/or competitor drugs in development. Model-based meta analysis enables indirect comparison, taking into account the impact of treatment, patient population, and trial characteristics. This type of analysis can help estimate the probability that a drug is superior than its competitors in the same drug class or across drug classes.

Endpoint-to-endpoint relationships
Our clinical outcomes databases contain large amount of data from published sources, which enables the applications of MBMA to make biomarker to clinical, and short-term to long- term endpoint predictions. Model-based meta-analysis can also be applied to scale across indications. These analysis help predict drug performance in later stage development, or in a different indication

Here are some excellent examples of the application of MBMA in drug development.